Insmed reported $-94621000 in Net Income for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
DBV Technologies DBVT:US -16706000 3.03M
Acelrx Pharmaceuticals ACRX:US $ -8.67M 0.76M
Alimera Sciences ALIM:US $ -5.96M 1.85M
Biomarin Pharmaceutical BMRN:US $ 120.8M 178.7M
Cytokinetics CYTK:US $ -89.44M 58.88M
Dynavax Technologies DVAX:US $ 32.86M 66.92M
Gilead Sciences GILD:US $ 19M 363M
Heron Therapeutics HRTX:US $ -63.89M 9.24M
Insmed INSM:US $ -94621000 18.36M
Mirati Therapeutics MRTX:US $ -188.39M 11.23M
Novartis NVS:US $ 2222M 14086M
Ophthotech OPHT:US $ -34.54M 1.5M
Regeneron Pharmaceuticals REGN:US $ 973.5M 1255.5M
Sarepta Therapeutics SRPT:US $ -105.02M 16.96M
Seattle Genetics SGEN:US $ -136.49M 38.13M
Ultragenyx Pharmaceutical RARE:US $ -152.32M 29.86M
Vertex Pharmaceuticals VRTX:US $ 762.1M 8.01M